Logo image
A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy
Journal article   Open access   Peer reviewed

A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy

May Cho, Jun Gong, Paul Frankel, Timothy W. Synold, Dean Lim, Vincent Chung, Joseph Chao, Daneng Li, Yuan Chen, Stephen Sentovich, …
Oncotarget, Vol.8(45)
2017

Abstract

binimetinib creatine kinase fluorouracil folinic acid oxaliplatin troponin I adult advanced cancer aged anaphylaxis anemia area under the curve Article ataxia blurred vision bone marrow suppression cancer combination chemotherapy cancer survival clinical article cohort analysis continuous dosing schedule diarrhea drug blood level drug dose escalation drug dose regimen drug efficacy drug hypersensitivity drug safety drug tolerability drug treatment failure drug withdrawal eye disease fatigue female gastrointestinal toxicity glaucoma half life time heart arrest human hypoxia intermittent dosing schedule limit of detection limit of quantitation liver function test male maximum plasma concentration metastatic colorectal cancer multiple cycle treatment nausea and vomiting neuropathy neutropenia oncogene K ras outcome assessment phase 1 clinical trial progression free survival rash retina vein occlusion side effect survival rate survival time thrombocytopenia visual impairment vitreous hemorrhage
Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment. Pharmacokinetic (PK) analysis of 5-FU and oxaliplatin was performed at the MTD in an expanded 6 patient cohort. Results: Twenty-six patients were enrolled and assessed for safety. In the doseescalation phase, no DLTs were noted in all binimetinib dosing schedules and the MTD of binimetinib in with FOLFOX was 45 mg orally twice daily. There were no significant differences in the PKs of 5-FU or oxaliplatin with or without binimetinib. Continuous dosing of binimetinib produced SD at 2 months in 9 of 13 evaluable patients and a median PFS of 3.5 months. Nine of 10 patients had PD at 2 months on the intermittent arm. Conclusions: Oral binimetinib and FOLFOX has a manageable toxicity profile and showed some evidence of antitumor activity in heavily pretreated mCRC patients. © Cho et al.
url
https://doi.org/10.18632/oncotarget.19336View
Published (Version of record) Open

Metrics

6 Record Views

Details

Logo image